Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer

Abstract

Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient’s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) in conjunction with IL-2 and immune-checkpoint blockade. Complete and durable tumor remission was observed after three TIL infusions consisting of 1.4×109, 2.0×109, and 8.0×109T cells, respectively, lasting now for more than 3.5 years. Immunological correlates to the clinical development were the decrease of tumor-driven NY-ESO-1 serum antibody and the drop of prostate-specific antigen to <0.01 µg/L. TILs were reactive against cancer-testis antigen NY-ESO-1, individual tumor mutational proteins (eg, PRPF8, TRPS1), and the androgen receptor splice variant 12.

Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis

“… Karbach et al (2023) report a male patient in his 70s to report a patient with PCa case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Shi et al (2018) present a case of an 82-year-old patient with prostatic adenocarcinoma and multiple bone metastases.…”

“… Karbach et al (2023) administered both Pembrolizumab and Tumor Infiltrating Lymphocytes (TIL). Pembrolizumab (4 doses) was given before every infusion of TIL (3 sessions) over 3 years ( Karbach et al, 2023 ).…”

“… Karbach et al (2023) administered both Pembrolizumab and Tumor Infiltrating Lymphocytes (TIL). Pembrolizumab (4 doses) was given before every infusion of TIL (3 sessions) over 3 years ( Karbach et al, 2023 ). Shi and colleagues (2018) used alloreactive Cytotoxic T lymphocyte (CTL) immunotherapy, after post-initial poor response to RT and chemotherapy.…”

“…Kumar et al (2019) report a 63-year-old male who was diagnosed with prostate adenocarcinoma, which was at first organ confined and shifted to hormone-refractory metastatic disease 4 years post-initial diagnosis. Karbach et al (2023) report a male patient in his 70s to report a patient with PCa case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Shi et al (2018) present a case of an 82-year-old patient with prostatic adenocarcinoma and multiple bone metastases.…”

“…APCEDEN was given in total over six doses, where the patient also received mitoxantrone to improve cell-mediated immunity (Kumar et al, 2019). Karbach et al (2023) administered both Pembrolizumab and Tumor Infiltrating Lymphocytes (TIL). Pembrolizumab (4 doses) was given before every infusion of TIL (3 sessions) over 3 years (Karbach et al, 2023).…”